Epocrates and M3 Partner to Create the World's Largest Physician Research Panel
Epocrates, Inc.
03.01.2012 15:15
---------------------------------------------------------------------------
SAN MATEO, Calif., 2012-01-03 15:15 CET (GLOBE NEWSWIRE) --
Two of the most respected market research sample providers in the industry,
Epocrates, Inc. (Nasdaq:EPOC) and M3 Inc. (TYO:2413), today announced a
partnership to create the world's largest verified physician and healthcare
provider panel. By combining their high-quality, opted-in physician panels, the
companies can now offer a global market research sampling solution.
The partnership offers research firms, pharmaceutical marketers and investors
greater access to qualified physicians and other healthcare professionals. The
new unified panel covers more than 70 countries with more than 1.7 million
physicians globally, providing more accurate targeting and sample specificity.
The top ten medical specialties worldwide are highly represented, including
oncology, cardiology and family practice.
The Epocrates market research panel is comprised of verified U.S. physicians
and other healthcare professionals who use the company's mobile clinical
reference application, creating stronger engagement and higher responsiveness.
It is recognized industry-wide for its honesty and sample representation,
providing clients the ability to recruit respondents based on specialty, years
in practice, geography and other demographic variables.
'An audit within the industry revealed that M3 has the same quality assurance
and values that we uphold for our research business,' said Peter Brandt,
interim president and chief executive officer of Epocrates. 'Together, we are
elevating the integrity and delivery standards across the research industry.'
M3 Inc. operates globally with physician communities across the world including
m3.com, MDLinx.com, Doctors.net.uk, Medquarter.de and Medigate.net. This
enabled the development of a proprietary healthcare professional panel with
international diversity and extensive reach. M3 is a founding member of the
Trust Alliance, recently introduced to promote trust in online physician
research.
'Both companies have established deep relationships with panel members,
providing faster turnaround and more quality responders all over the world,'
said Aki Tomaru M3's U.S. CEO. 'The goal of this partnership is to create some
of the best healthcare market research coverage globally, featuring more
consistent and comprehensive solutions for the industry.'
About Epocrates, Inc.
Epocrates, Inc. (Nasdaq:EPOC) is a leading physician platform for essential
clinical content, practice tools and health industry engagement at the point of
care. The Epocrates network consists of more than 1.4 million healthcare
professionals, including 50 percent of U.S. physicians, who routinely use its
solutions and services. Epocrates' portfolio includes top-ranked medical apps,
such as the industry's #1 most used mobile drug reference, valuable
manufacturer resources, and a SaaS web-based electronic health record. Through
these intuitive and reliable resources, the company supports clinical
decisions, helps improve physician workflow and impacts patient outcomes. For
more information, please visit www.epocrates.com/company.
The Epocrates, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=10943
About M3 Inc.
M3 Global Research is the market research division of Tokyo-based M3 Inc.
(TYO:2413) operating globally with a proprietary healthcare professionals panel
of 1.3 million respondents in more than 60 countries. The division was created
by uniting the worldwide healthcare panels of M3 companies and exclusive
partners across the USA, Europe, Asia, and Latin America. M3 Global Research
offers a broad range of capabilities including quantitative, qualitative
utilizing call centers and in-country project managers. M3 has provided
solutions for every top 20 pharmaceutical company in the world. For more
information, visit http://research.m3.com.
Forward-Looking Statements
Certain statements contained in this press release are forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements by their nature address matters that are,
to different degrees, uncertain. Uncertainties and risks may cause Epocrates'
actual results to be materially different than those expressed in or implied by
Epocrates' forward-looking statements. For Epocrates, particular uncertainties
and risks include, among others: unexpected delays in Epocrates delivering new
products may occur, which would cause revenues not to be as Epocrates expects;
market acceptance of new products, and new partnerships such as the one
described above with M3 Inc., may not be as Epocrates expects, which would
cause revenues not to be as Epocrates expects; and the impact of competitive
products and pricing may decrease demand for Epocrates' products and/or force
Epocrates to decrease the price of its products. More detailed information on
these and additional factors that could affect Epocrates' actual results are
described in Epocrates' filings with the Securities and Exchange Commission,
including its Annual Report on Form 10-K filed with the Securities and Exchange
Commission on March 31, 2011. Except as required by law, Epocrates undertakes
no obligation to publicly update its forward-looking statements.
CONTACT: Erica Sniad Morgenstern
Senior Director, Public Relations and Communication
Epocrates, Inc.
(650) 227-6907
pr@epocrates.com
News Source: NASDAQ OMX
03.01.2012 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Epocrates, Inc.
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US29429D1037
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Epocrates, Inc.
03.01.2012 15:15
---------------------------------------------------------------------------
SAN MATEO, Calif., 2012-01-03 15:15 CET (GLOBE NEWSWIRE) --
Two of the most respected market research sample providers in the industry,
Epocrates, Inc. (Nasdaq:EPOC) and M3 Inc. (TYO:2413), today announced a
partnership to create the world's largest verified physician and healthcare
provider panel. By combining their high-quality, opted-in physician panels, the
companies can now offer a global market research sampling solution.
The partnership offers research firms, pharmaceutical marketers and investors
greater access to qualified physicians and other healthcare professionals. The
new unified panel covers more than 70 countries with more than 1.7 million
physicians globally, providing more accurate targeting and sample specificity.
The top ten medical specialties worldwide are highly represented, including
oncology, cardiology and family practice.
The Epocrates market research panel is comprised of verified U.S. physicians
and other healthcare professionals who use the company's mobile clinical
reference application, creating stronger engagement and higher responsiveness.
It is recognized industry-wide for its honesty and sample representation,
providing clients the ability to recruit respondents based on specialty, years
in practice, geography and other demographic variables.
'An audit within the industry revealed that M3 has the same quality assurance
and values that we uphold for our research business,' said Peter Brandt,
interim president and chief executive officer of Epocrates. 'Together, we are
elevating the integrity and delivery standards across the research industry.'
M3 Inc. operates globally with physician communities across the world including
m3.com, MDLinx.com, Doctors.net.uk, Medquarter.de and Medigate.net. This
enabled the development of a proprietary healthcare professional panel with
international diversity and extensive reach. M3 is a founding member of the
Trust Alliance, recently introduced to promote trust in online physician
research.
'Both companies have established deep relationships with panel members,
providing faster turnaround and more quality responders all over the world,'
said Aki Tomaru M3's U.S. CEO. 'The goal of this partnership is to create some
of the best healthcare market research coverage globally, featuring more
consistent and comprehensive solutions for the industry.'
About Epocrates, Inc.
Epocrates, Inc. (Nasdaq:EPOC) is a leading physician platform for essential
clinical content, practice tools and health industry engagement at the point of
care. The Epocrates network consists of more than 1.4 million healthcare
professionals, including 50 percent of U.S. physicians, who routinely use its
solutions and services. Epocrates' portfolio includes top-ranked medical apps,
such as the industry's #1 most used mobile drug reference, valuable
manufacturer resources, and a SaaS web-based electronic health record. Through
these intuitive and reliable resources, the company supports clinical
decisions, helps improve physician workflow and impacts patient outcomes. For
more information, please visit www.epocrates.com/company.
The Epocrates, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=10943
About M3 Inc.
M3 Global Research is the market research division of Tokyo-based M3 Inc.
(TYO:2413) operating globally with a proprietary healthcare professionals panel
of 1.3 million respondents in more than 60 countries. The division was created
by uniting the worldwide healthcare panels of M3 companies and exclusive
partners across the USA, Europe, Asia, and Latin America. M3 Global Research
offers a broad range of capabilities including quantitative, qualitative
utilizing call centers and in-country project managers. M3 has provided
solutions for every top 20 pharmaceutical company in the world. For more
information, visit http://research.m3.com.
Forward-Looking Statements
Certain statements contained in this press release are forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements by their nature address matters that are,
to different degrees, uncertain. Uncertainties and risks may cause Epocrates'
actual results to be materially different than those expressed in or implied by
Epocrates' forward-looking statements. For Epocrates, particular uncertainties
and risks include, among others: unexpected delays in Epocrates delivering new
products may occur, which would cause revenues not to be as Epocrates expects;
market acceptance of new products, and new partnerships such as the one
described above with M3 Inc., may not be as Epocrates expects, which would
cause revenues not to be as Epocrates expects; and the impact of competitive
products and pricing may decrease demand for Epocrates' products and/or force
Epocrates to decrease the price of its products. More detailed information on
these and additional factors that could affect Epocrates' actual results are
described in Epocrates' filings with the Securities and Exchange Commission,
including its Annual Report on Form 10-K filed with the Securities and Exchange
Commission on March 31, 2011. Except as required by law, Epocrates undertakes
no obligation to publicly update its forward-looking statements.
CONTACT: Erica Sniad Morgenstern
Senior Director, Public Relations and Communication
Epocrates, Inc.
(650) 227-6907
pr@epocrates.com
News Source: NASDAQ OMX
03.01.2012 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Epocrates, Inc.
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US29429D1037
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------